Shenzhen Bioeasy Biotechnology Co. Ltd. Cash Flow-to-Debt Ratio
Shenzhen Bioeasy Biotechnology Co. Ltd. cash flow-to-debt ratio. Shenzhen Bioeasy Biotechnology Co. Ltd. (300942) has a Cash Flow-to-Debt Ratio of 0.02x as of September 2025, meaning its operating cash flow of CN¥9.12 Million could theoretically repay 0% of its total liabilities (CN¥571.21 Million) in one year. Check 300942 total capital reinvestment ratio to assess the company's total reinvestment commitment from operating cash flow.
CF-to-Debt Ratio
Operating Cash Flow
Total Liabilities
Data as of
Cash Flow-to-Debt Ratio of Shenzhen Bioeasy Biotechnology Co. Ltd. (2016–2025)
Cash flow-to-debt ratio of Shenzhen Bioeasy Biotechnology Co. Ltd. from 2016 to 2025. Historical debt coverage capacity for Shenzhen Bioeasy Biotechnology Co. Ltd. across 10 annual periods. Check 300942 cash flow quality index to evaluate the quality of earnings relative to operating cash generation.
Shenzhen Bioeasy Biotechnology Co. Ltd. Cash Flow-to-Debt Ratio by Year (2016–2025)
Shenzhen Bioeasy Biotechnology Co. Ltd. cash flow-to-debt ratio by year from 2016 to 2025. Year-by-year debt coverage analysis for Shenzhen Bioeasy Biotechnology Co. Ltd.. For the full cash flow conversion analysis, see 300942 cash flow conversion.
| Year | CF-to-Debt Ratio | Operating CF (CNY) | Total Liabilities | YoY Change |
|---|---|---|---|---|
| 2025 | 0.11x | CN¥66.87 Million | CN¥616.87 Million | ▲ +85.7% |
| 2024 | 0.06x | CN¥34.26 Million | CN¥586.92 Million | ▲ +179.5% |
| 2023 | -0.07x | CN¥-37.25 Million | CN¥507.61 Million | ▼ -115.3% |
| 2022 | 0.48x | CN¥152.55 Million | CN¥317.75 Million | ▼ -61.3% |
| 2021 | 1.24x | CN¥255.42 Million | CN¥205.94 Million | ▲ +102.0% |
| 2020 | 0.61x | CN¥63.79 Million | CN¥103.90 Million | ▼ -16.6% |
| 2019 | 0.74x | CN¥67.24 Million | CN¥91.35 Million | ▼ -5.7% |
| 2018 | 0.78x | CN¥57.93 Million | CN¥74.22 Million | ▲ +95.8% |
| 2017 | 0.40x | CN¥23.60 Million | CN¥59.19 Million | ▼ -25.5% |
| 2016 | 0.54x | CN¥36.31 Million | CN¥67.83 Million | — |